Barinthus Biotherapeutics plc.
Nasdaq · CIK 0001828185 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-6.1M
Net Income
$-5.5M
Eps Basic
-0.14
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-6.1M | - | - |
| Net Income | $-5.5M | - | - |
| Eps Basic | -0.14 | - | - |
| Eps Diluted | -0.14 | - | - |
| Cash And Equivalents | $65.9M | - | - |
| Total Assets | $92.1M | - | - |
| Total Liabilities | $25.7M | - | - |
| Shareholders Equity | $66.4M | - | - |
| Operating Cash Flow | $-3.4M | - | - |
| Capital Expenditures | $0 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Barinthus Biotherapeutics plc. | 2026-04-30 | 0001828185-26-000019 |
| 10-K | Barinthus Biotherapeutics plc. | 2026-03-13 | 0001828185-26-000012 |
| 10-Q | Barinthus Biotherapeutics plc. | 2025-11-07 | 0001828185-25-000072 |
| 10-Q | Barinthus Biotherapeutics plc. | 2025-08-07 | 0001828185-25-000059 |